US equities
|
AAPL
$331.90
▼-1.90%
NVDA
$206.69
▲+2.29%
MU
$855.10
▲+2.58%
AMD
$483.90
▲+3.65%
ORCL
$126.19
▲+5.85%
TSLA
$398.50
▼-1.32%
MSFT
$520.99
▲+2.74%
SPCX
$141.31
▲+3.62%
AAPL
$331.90
▼-1.90%
NVDA
$206.69
▲+2.29%
MU
$855.10
▲+2.58%
AMD
$483.90
▲+3.65%
ORCL
$126.19
▲+5.85%
TSLA
$398.50
▼-1.32%
MSFT
$520.99
▲+2.74%
SPCX
$141.31
▲+3.62%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
NeOnc Technologies Holdings, Inc. - Common Stock
(NQ:
NTHI
)
3.070
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NeOnc Technologies Holdings, Inc. - Common Stock
< Previous
1
2
3
4
Next >
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
November 02, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
October 22, 2026
Segment to air Sunday, October 25, at 5:30 p.m. ET on Fox Business Network
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.
From
FN Media
Via
GlobeNewswire
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
October 21, 2026
Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story
Via
Newsfile
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
October 21, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
October 16, 2026
Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential...
Via
Newsfile
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
October 16, 2026
Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of investigational treatment
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
October 15, 2026
With UAE authorizations for both lead drug candidates, NeOnc brings a clinical development perspective to discussions on capital, precision medicine and international collaboration
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
October 14, 2026
Appointment strengthens financial governance and supports NeOnc’s clinical development and expansion in Abu Dhabi
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
September 28, 2026
November 17 meeting will address Phase 2 study design and potential regulatory pathways
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
September 17, 2026
Cash redemption simplifies the capital structure with no common shares issued in the redemption
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
September 16, 2026
CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive NEO100 Phase 2a results
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
September 09, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
New to The Street Airs This Weekend Across Bloomberg Television U.S., Latin America and MENA
August 15, 2026
From
New to The Street
Via
ACCESS Newswire
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
August 13, 2026
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on...
Via
Newsfile
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
August 12, 2026
Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal...
Via
Newsfile
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 12, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
August 11, 2026
Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high...
Via
Newsfile
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
August 10, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 10, 2026
Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
July 27, 2026
Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
July 15, 2026
FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
June 23, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
June 22, 2026
Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend...
Via
Newsfile
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
June 16, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
June 15, 2026
Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology...
Via
Newsfile
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
June 09, 2026
Houston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intelligence has dominated conversations surrounding the future of healthcare...
Via
Newsfile
Topics
Artificial Intelligence
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
May 18, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
May 05, 2026
From
NeOnc Technologies Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
